Allergy Therapeutics plc has received a public opening position disclosure/dealing disclosure from Cavendish Securities Plc, an exempt principal trader. The disclosure is made in accordance with Rule 8.5 of the Takeover Code. Cavendish Securities Plc is connected to Allergy Therapeutics plc, the offeror/offeree in this case. The date of the position held/dealing undertaken is 24/10/23.
In terms of positions, Cavendish Securities Plc owns and/or controls 279,288 relevant securities of Allergy Therapeutics plc, which represents 0.01% of the total. There are no cash-settled derivatives or stock-settled derivatives (including options) and agreements to purchase/sell. All interests and short positions have been disclosed.
Regarding dealings, Cavendish Securities Plc has made sales of 4,000 securities of Allergy Therapeutics plc at a highest price per unit of 1.57 and a lowest price per unit of 1.57. There are no cash-settled derivative transactions or stock-settled derivative transactions (including options). No other dealings, such as subscribing for new securities, have been reported.
There are no indemnity or other dealing arrangements, agreements, arrangements, or understandings relating to options or derivatives between Cavendish Securities Plc and any other person. No supplemental form 8 (open positions) is attached to the disclosure.
The disclosure was made on 25/10/23 by Angela Teodorescu, with a contact number of 02037724641. Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation regarding the Code's disclosure requirements.